Whole-body effective half-life of radioiodine in children and young adults with papillary thyroid cancer
- PMID: 39893603
- DOI: 10.1007/s12020-025-04183-1
Whole-body effective half-life of radioiodine in children and young adults with papillary thyroid cancer
Abstract
Purpose: The lack of radioiodine-131 (RAI) kinetic study is a serious challenge for rational dosing for children and young adults (CYAs) with papillary thyroid cancer (PTC). The present study was conducted to investigate the whole-body effective half-life (EHL) and absorbed dose in RAI ablative therapy of CYAs with PTC.
Methods: In the period 2017-2022, all consecutive PTC patients 20 years or younger prepared for ablative RAI therapy after thyroid hormone withdrawal were prospectively recruited. Serial whole-body dose-rate measurements after administration were performed to deduce whole-body RAI retention. Calculations based on the deduced whole-body retention and the schema of Medical Internal Radiation Dosimetry were derived to determine whole-body EHL and absorbed doses. A multivariate linear regression analysis was employed to assess the association between whole-body EHL and potential predictors.
Results: A total of 52 patients (median age 17 years [range, 6-20 years]) were recruited. The mean whole-body EHL (±SD) was 10.3 (3.3) hours (median, 9.4 h [range, 6.3-21.7 h]). In univariable linear regression analysis, whole-body EHL was significantly associated with gender, body surface area (BSA) and body mass index (p < 0.05). Creatinine, Cystatin C, glomerular filtration rate (GFR) and positive post-ablation scintigraphy approached significance with respect to EHL (p ≤ 0.2 and ≥0.05). At multivariable analysis, BSA, GFR and positive post-ablation scintigraphy was associated with EHL. A median activity of 3.7 GBq of RAI (range, 1.85-7.40 GBq) was administered and a median whole-body absorbed dose of 0.22 Gy was delivered (range, 0.11-0.79 Gy).
Conclusion: A wide variation of whole-body EHL was observed in CYAs with PTC treated with RAI. The whole-body EHL is significantly longer in CYAs with larger BSA, decreased GFR and presence of extra-thyroidal disease. Understanding these predictors may improve our ability to dosing strategies in RAI therapy of CYAs with PTC.
Keywords: Children and young adults; Papillary thyroid cancer; Radioiodine-131 therapy; Whole-body absorbed dose; Whole-body effective half-life.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with ethical standards. Conflict of interest: The authors declare no competing interests. Ethical approval and consent to participate: The original survey protocol was approved by the Institutional Review Board of West China Hospital, Sichuan University. The requirement of written informed consent was waived by the ethics committee. Consent for publication: All authors read the manuscript and agreed to its publication.
Similar articles
-
Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.J Nucl Med. 2019 May;60(5):631-637. doi: 10.2967/jnumed.118.217638. Epub 2018 Oct 12. J Nucl Med. 2019. PMID: 30315143
-
Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.Front Endocrinol (Lausanne). 2021 Dec 16;12:795184. doi: 10.3389/fendo.2021.795184. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34975765 Free PMC article.
-
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.Thyroid. 2012 Sep;22(9):877-83. doi: 10.1089/thy.2011.0429. Epub 2012 Jul 24. Thyroid. 2012. PMID: 22827641
-
Long-term Follow-up of a Toddler with Papillary Thyroid Carcinoma: A Case Report with a Literature Review of Patients Under 5 Years of Age.J Clin Res Pediatr Endocrinol. 2022 Mar 3;14(1):119-125. doi: 10.4274/jcrpe.galenos.2020.2020.0178. Epub 2021 Jan 15. J Clin Res Pediatr Endocrinol. 2022. PMID: 33448212 Free PMC article. Review.
-
Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.Clin Endocrinol (Oxf). 2024 Feb;100(2):181-191. doi: 10.1111/cen.15001. Epub 2023 Dec 4. Clin Endocrinol (Oxf). 2024. PMID: 38050454
References
-
- X Zhang, L Jiang, L Liu, B Liu, Influence of body mass index at diagnosis on outcome of thyroid cancer in children and adolescents. Surgery 169(6), 1373–1378 (2021). https://doi.org/10.1016/j.surg.2020.12.047 . - DOI - PubMed
-
- Y. Wei, L. Xiao, L. Liu, L. Shi, Y. Wang, B. Liu, Prognostic implications of lymph node yield in pediatric patients with N1b papillary thyroid cancer. Oral. Oncol. 158, 106984 (2024). https://doi.org/10.1016/j.oraloncology.2024.106984 - DOI - PubMed
-
- Y Xu, L Shi, J Wu, H Li, Y Wang, B Liu, Prognostic value of tumor multifocality in pediatric papillary thyroid carcinoma: a Real-Life Multicentric Study. Otolaryngol. Head. Neck Surg. 169(6), 1606–1614 (2023). https://doi.org/10.1002/ohn.373 . - DOI - PubMed
-
- G.L Francis, S.G Waguespack, A.J Bauer, P Angelos, S Benvenga, J.M Cerutti, C.A Dinauer, J Hamilton, I.D Hay, M Luster, M.T Parisi, M Rachmiel, G.B Thompson, S Yamashita, Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25(7), 716–759 (2015). https://doi.org/10.1089/thy.2014.0460 . - DOI - PubMed - PMC
-
- C Dinauer, G.L Francis, Thyroid cancer in children. Endocrinol. Metab. Clin. North. Am. 36(3), 779–806 (2007). https://doi.org/10.1016/j.ecl.2007.04.002 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical